This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Narrowing post #30, because the general version has more than one answer.
On variability: the between-person spread in exposure for oral semaglutide is wide enough that two people on the same dose can have quite different plasma concentrations. That is inherent to the absorption route.
Everything in post #28 holds. The case it does not cover is the one I have.
Taking the oral product with more water than instructed reduces absorption rather than helping it. That is counter-intuitive and it is one of the few dosing instructions in this field with a clear pharmacokinetic basis.
Not the whole picture, but the part of it I can speak to.
PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial. Non-inferiority for safety was demonstrated. The point estimates favoured the drug but the trial was not designed to establish benefit.
Noting that I have skin in this question and have tried to discount for it.
Oral semaglutide bioavailability is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
Oral bioavailability is variable between people. Some people absorb well; others absorb poorly. That inter-individual variation is larger than with injectables and is one reason the trial data for oral formulations receives different treatment.
Answering the question post #32 raises rather than the one it answers.
The SOUL trial: cardiovascular outcomes trial for oral semaglutide in people with type 2 diabetes and cardiovascular disease or chronic kidney disease. It demonstrates that benefit appears to be a property of the molecule and exposure, not specific to the route.
Dose equivalence between oral and injectable formulations is not a simple conversion and no published factor should be used as one. The two were developed and titrated separately.
I would treat that as a working assumption and revisit it.
Fasting instructions are not optional advice. Taking the tablet with food or with more than a sip of water measurably reduces absorption. This is the one compound in the class where the instructions genuinely determine the exposure.
Filing this under things that are true until someone shows me otherwise.
PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial. Non-inferiority for safety was demonstrated. The point estimates favoured the drug but the trial was not designed to establish benefit.
It took me longer than it should have to see that.
Picking up post #41: that is the part I would want checked first.
Tablet integrity matters more than people expect for a formulation that depends on an absorption enhancer released at a particular place. Splitting or crushing is not a dose adjustment; it is a different product.
I had written a reply contradicting post #41 and deleted it. Here is what survived.
The practical argument for an oral is adherence, and the published adherence data is less flattering than the argument. Daily dosing with fasting requirements is not obviously easier than a weekly injection.
Dose numbers for oral formulations are not comparable to injectable ones. The 14 mg oral dose is not equivalent to any injectable dose in the traditional comparison sense. They are different formulations with different pharmacokinetics and cannot be put on the same scale.
I have kept the units in throughout, for the obvious reason.
Orforglipron is a small molecule rather than a peptide, which changes almost everything about how it is made, stored and analysed. Comparing it to oral semaglutide as though they were the same pharmaceutical problem is a category error.
The part I am sure of is shorter than the part I have written.
Seconded. It reads as careful rather than confident, which is the right register.
Coming back to post #45, because the follow-up matters more than the original answer.
SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer that transiently raises local pH in the stomach and promotes gastric mucosal absorption. Without it, oral bioavailability of semaglutide would be too low for clinically useful dosing.
Post #45 is right about the mechanism and I think understates the practical bit.
A definition problem is doing most of the work in this Oral semaglutide bioavailability discussion. Once the term is pinned down I suspect the disagreement mostly goes away and what is left is small.
Oral semaglutide's bioavailability is low and variable, which is why the dose numbers are an order of magnitude different from the injectable. That is a formulation consequence and not a difference in potency.
PIONEER 6 is the cardiovascular outcome trial for oral semaglutide and it enrolled a diabetes population at high cardiovascular risk. Quoting it outside that population is an extrapolation.
It is a small point and it changes the answer, which is an awkward combination.
Post #51 is the version of this I will quote in future. One addition.
Trial adherence in an oral trial with strict administration requirements is genuinely worse than trial-published data often suggests. That is why the exposure variability in oral formulations is mentioned repeatedly in the discussions here.
The short version is the first sentence; the rest is why.
Where I part company with post #50, and it is a narrow parting.
Oral versus injectable exposure: comparing a 14 mg oral dose with a 0.5 mg injectable dose is comparing apples to a different fruit. The oral bioavailability is low enough that dose numbers are an order of magnitude different and not directly comparable.
The uncertainty is in the assumption, not in the calculation.
Anyone comparing published oral and injectable efficacy should check whether the comparison is within one trial or across two. Across two, the populations differ and the comparison is weak.
I have said this before in a thread nobody could find, so it is worth repeating.
Post #54 describes the usual case. This is about the unusual one.
Research-use-only oral material is not a licensed tablet and there is no reason to assume it carries a functioning absorption-enhancement system at all. The formulation is most of the product here.
Old habit: I write down the expected answer before I calculate it.
Confirming post #56 from a second method, which matters more than confirming it from a second person.
The absorption enhancer in the licensed oral product works by transiently raising local gastric pH and promoting absorption across the mucosa. It is the reason the fasting and water-volume instructions are specific rather than cautious.
Two questions I would want answered before drawing anything from the Oral semaglutide bioavailability data above: how were the cases selected, and what happened to the ones that dropped out.
Useful. I had the fact and not the reason, which turns out to be the important half.
On post #58 — agreed on the reasoning, with one qualification.
On variability: the between-person spread in exposure for oral semaglutide is wide enough that two people on the same dose can have quite different plasma concentrations. That is inherent to the absorption route.